Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care

This activity was originally broadcast in conjunction with AMCP 2025.

Program Description

HIV is a chronic condition affecting over 1 million people in the United States, and many people living with HIV experience systemic barriers to care that limit treatment access and adherence. Long-acting injectables (LAIs) have extended the administration schedule for antiretroviral regimens, but challenges in the management of these therapies still remain. Pharmacists practicing in managed care can be central to identifying people with increased risk behaviors for HIV transmission, reviewing evidence-based recommendations for inclusion of LAIs within formularies and treatment protocols, and monitoring for treatment adherence and efficacy. Additionally, ensuring that people who are eligible for preexposure prophylaxis (PrEP) requires that managed care professionals and pharmacists implement projects designed to improve the uptake of PrEP LAIs. This session will review key aspects of improving access and adherence to LAIs, including programs emphasizing equitable implementation in HIV care and real-time decision-making with patients. Detailed information on the route of administration and dosing schedules for LAIs and how they can be effectively incorporated into HIV care plans will also be discussed.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: April 9, 2025
Expiration date: April 9, 2026

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify patient populations who may benefit from HIV long-acting injectables (LAIs) based on clinical guidelines, risk factors, and patient preferences.
• Differentiate between the various HIV LAIs available, including their mechanisms of action, dosing regimens, and appropriate indications for use.
• Apply managed care strategies to optimize the uptake of HIV LAIs among eligible patients, including coverage policies, patient education, and provider engagement initiatives.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-080-H02-P. The activity is available for CE credit through April 9, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Josh Havens, PharmD, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Gilead Sciences; Consultant: Merck, ViiV Healthcare.

Jordan Almazan, PharmD, has the following financial relationship with a commercial interest to disclose:
Employee of PBM: Prime Therapeutics, senior director of clinical strategy and innovation (product development).

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms